Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag Retrospective Observational Study in Pulmonary Arterial Hypertension
jRCT1051220173Recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Nippon Shinyaku. Started Jan 2023; status: recruiting.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT1051220173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051220173.